BSG005
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Invasive Fungal Infection
Conditions
Invasive Fungal Infection
Trial Timeline
Jul 1, 2024 → Apr 1, 2026
NCT ID
NCT06678113About BSG005
BSG005 is a phase 1/2 stage product being developed by Alkem Laboratories for Invasive Fungal Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06678113. Target conditions include Invasive Fungal Infection.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06678113 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Invasive Fungal Infection